Introduction {#s1}
============

Following stimulation via the TcR, selective differentiation of T helper cell subsets is dependent on transcription factors, with Bcl-6 being responsible for T follicular helper (Tfh) cell differentiation ([@bib19]; [@bib7]) and antagonism of other T cell phenotypes (Th1, Th2, Th17). Gene knockout studies in mice have revealed the requirement for CD28 mediated-costimulation in the upstream control of Tfh differentiation ([@bib23]), with subsequent signalling through inducible T cell costimulator (ICOS) involved in consolidation of differentiation ([@bib9]; [@bib45]). The mechanisms controlling the induction of this differentiation program are less clear, a role for the cytokines IL-6 and IL-21 and subsequent signalling via STAT3 have been implicated ([@bib32]), while other studies indicate that the strength and duration of the T cell receptor (TCR) signal itself is the major factor determining effector cell differentiation to Tfh ([@bib11a]; [@bib42]). Using well defined and controlled conditions that preferentially induce Tfh responses in vivo, we have therefore adopted a reductionist approach to determine which of these factors are important in the differentiation of this subset in vivo.

A variety of particle formulations, including alum, emulsions and liposomes have received sustained interest as vaccine adjuvants for over 80 years ([@bib5]; [@bib44]; [@bib10]). Their ability to affect the availability of antigen and antigen presentation has frequently been linked to their impact on the development of T cell responses ([@bib8]), but causal evidence has been absent. More recently, studies have suggested that the use of nanoparticles as adjuvants can selectively induce Tfh responses ([@bib29]). Clearly selective differentiation of Tfh effector cells has implications in vaccine design and pathogen control as for the majority of vaccines the principal effector mechanism induced is production of high affinity, class switched antibodies by B lymphocytes. Here we employ defined antigen particles to selectively induce Tfh cells and antibody responses and show that increased duration of antigen presentation and subsequent T cell/dendritic cell (DC) interactions are associated with Tfh induction. The functional significance of these late stage (72 hr) interactions in T cell differentiation was demonstrated by blockade of T/DC interactions in vivo. These studies demonstrate that by manipulating the form of antigen delivered late stage antigen presentation by DC and their interaction with T cells can be controlled to drive Tfh differentiation in vivo.

Results {#s2}
=======

Antigen size impacts on protective humoral immunity {#s2-1}
---------------------------------------------------

In the present study, we employed polystyrene nanoparticles due to their inert nature, defined size, narrow polydispersity, and surface functionalisation allowing covalent linkage of antigen to their surface. Polystyrene nanoparticles do not induce ERK activity or subsequent activation of conventional inflammatory pathways in DC ([@bib20]). Our study focused on polystyrene nanoparticle sizes able to drain freely to the LN ([@bib25]). Carbodiimide-mediated coupling of antigens was highly controlled, such that only particle size and physically dependent parameters (surface area, antigen molecules per particle) varied between immunisation conditions; all other conditions, antigen dose, mass of particles, and antigen density were consistent between 40 nm and 200 nm particle immunisations ([Table 1](#tbl1){ref-type="table"}). Consequently, immunisations with equivalent quantities of protein were not associated with any confounding difference in total antigenic mass and a single variable, particle size could be tested for its impact on antigen specific immune responses. Initial experiments investigating the effect of particle size on antibody responses revealed that immunisation of mice with Ag covalently linked to 200 nm particles induced significantly higher amounts of specific IgG1 and IgG2c than smaller particles or soluble Ag ([Figure 1A,B](#fig1){ref-type="fig"}). 1000 nm particles failed to induce an antibody response, potentially due to a failure in uptake by APCs and/or ability to drain to the LN. Subsequent studies thus focussed on the significance and processes by which the 200 nm particles were able to support this antibody response, in comparison to smaller particles (40 nm) and soluble antigen that did not.10.7554/eLife.06994.003Table 1.Comparison of particle conjugates**DOI:** [http://dx.doi.org/10.7554/eLife.06994.003](10.7554/eLife.06994.003)Particle size40 nm200 nmAntigen dose/mouse100 μg100 μgAntigen molecules/mouse1.3 × 10^15^1.3 × 10^15^Latex dose/mouse100 μg130 μgNumber of particles/mouse1.4 × 10^12^2.9 × 10^10^Antigen molecules/particle100020,000Surface area/particle5024 nm^2^125,600 nm^2^Antigen density1 per 5 nm^2^1 per 6 nm^2^[^1]10.7554/eLife.06994.004Figure 1.Immunisation with antigen loaded 200 nm particles induces elevated IgG and can provide protective immunity to influenza virus infection.Mice were immunised s.c. in the scruff with 100 μg of ovalbumin (OVA) alone or conjugated to 20 nm, 40 nm, 100 nm, 200 nm or 1000 nm particles. 14 days later, serum was tested by ELISA for anti-OVA-IgG2c (**A**) and anti-OVA-IgG1 (**B**). Data show the mean (−) absorbance (405 nm) at a dilution of 1 in 200 with the five experimental animals per group (′) \*\*\*p \< 0.001 comparing to the PBS group. To assess functional responses, C57BL/6 mice were immunised s.c. with 50 μg of hemagglutinin (HA) alone, conjugated to 40 or 200 nm particles, or emulsified with complete Freund\'s adjuvant (CFA). Weight changes were then monitored following intranasal infection with 300 PFU of influenza A virus (WSN) (**C**). Data shows the mean of five experimental animals per group ± standard deviation \*\*\*p \< 0.001 comparing 200 nm group to 40 nm group.**DOI:** [http://dx.doi.org/10.7554/eLife.06994.004](10.7554/eLife.06994.004)

The functional importance of the observed antigen specific antibody response was evaluated in a murine influenza virus infection model where antibodies to the hemagglutinin (HA) component of influenza virus are important to protective immunity ([@bib31]; [@bib14]), blocking viral attachment and fusion of the viral and host cell membrane ([@bib21]). Three weeks after immunisation with HA linked to 200 or 40 nm particles, emulsified in complete Freund\'s adjuvant (CFA) or as soluble protein, mice were challenged intranasally with influenza A virus (H1N1; A/WSN/1933 \[WSN\]). Protection from infection was determined by weight loss ([Figure 1C](#fig1){ref-type="fig"}). While mice immunised with 200 nm HA-particles were protected from virus induced pathology, significant weight loss was observed in groups immunised with 40 nm HA-particles, similar weight loss to that observed in unimmunised or soluble HA treated mice.

Antigen size influences the development of Tfh and B cell responses {#s2-2}
-------------------------------------------------------------------

To delineate the mechanisms that allow particle size to control antibody responses, we employed an established adoptive transfer model ([@bib12]). Antigen specific CD4^+^ T cells and B cells were co-transferred into congenic recipients then immunised with 130 μg of ovalbumin (OVA)-hen egg lysozyme (HEL) conjugate alone, in CFA or bound to 40 nm or 200 nm particles. Analysis of serum samples collected 10 days post immunisation revealed OVA-HEL conjugated to 200 nm particles induced significant levels of serum anti-HEL-IgM^a^, whereas antigen conjugated to 40 nm particles did not ([Figure 2A](#fig2){ref-type="fig"}). Similarly, antigen conjugated to 200 nm particles induced greater expansion of antigen-specific IgM^a+^ MD4 B cells than challenge with 40 nm particles 7 days post immunisation ([Figure 2B](#fig2){ref-type="fig"}). Enhanced expression of germinal centre (GC) markers (GL7 and FAS) following immunisation with 200 nm OVA-HEL particles compared with 40 nm OVA-HEL particles was also evident ([Figure 2C,D](#fig2){ref-type="fig"}). Conventional GC responses are dependent on activated, antigen-specific CD4^+^ T cells ([@bib36]; [@bib33]), suggesting that different particles could induce changes in the magnitude or phenotype of the resulting T cell response. However, immunisation with OVA-HEL conjugated to either 40 nm or 200 nm particles could equally increase the proportion and number of antigen specific OT-II T cells in vivo ([Figure 3A,B](#fig3){ref-type="fig"}), consistent with a previous report ([@bib13]). This implied that particle size induced a qualitative rather than quantitative difference in T cell response, favouring generation of the Tfh subset of T cells that have been defined as supporting B cell responses and GC formation ([@bib24]). Analysis of Tfh markers CXCR5, PD-1, ICOS and SLAM by adoptively transferred OT-II T cells demonstrated the percentage and number of antigen specific cells differentiating into Tfh cells was very low at day 5 post immunisation with soluble antigen or antigen conjugated to 40 nm particles ([Figure 3C--E](#fig3){ref-type="fig"}). However, a significant proportion of OT-II T cells were CXCR5^+^PD-1^+^ following challenge with OVA-HEL conjugated to 200 nm particles ([Figure 3C--E](#fig3){ref-type="fig"}). Changing a single physical characteristic of the immunising antigen selectively enhanced Tfh differentiation without impacting on the magnitude of T cell response, providing an excellent platform to dissect how external stimuli can contribute to Tfh development in vivo.10.7554/eLife.06994.005Figure 2.Immunisation with antigen loaded 200 nm particles enhances B cell expansion and germinal centre (GC) B cell responses.To dissect the cellular responses in detail, MD4 BcR transgenic (Tg) B cells and OT-II TcR Tg T cells and were adoptively transferred into C57BL/6 recipients. Mice were then challenged with OVA-hen egg lysozyme (HEL) conjugated to 40 nm or 200 nm particles. Challenges with PBS, OVA-HEL alone or in CFA were included as negative and positive controls. Day 10 serum samples were assayed by ELISA to determine anti-HEL-IgM^a^ levels (**A**). Expansion of B220^+^IgM^a+^ MD4 B cells in popliteal LNs was assessed by flow cytometry 7 days post challenge (**B**). Development of GC B cell responses was determined by examining GL7 and FAS expressing by MD4 B220^+^ cells (**C**). Representative staining of GC markers GL7 and FAS are also shown (**D**). Panels show mean value and five individual animals in a representative experiment of 3.**DOI:** [http://dx.doi.org/10.7554/eLife.06994.005](10.7554/eLife.06994.005)10.7554/eLife.06994.006Figure 3.200 nm particles induce T follicular helper (Tfh) differentiation.MD4 BcR Tg B cells and OT-II TcR Tg T cells and were adoptively transferred into C57BL/6 recipients. Mice were then challenged with OVA-HEL conjugated to 40 nm or 200 nm particles. Challenges with PBS, OVA-HEL alone or in CFA were included as negative and positive controls. CD4^+^DsRed^+^ OT-II cell expansion in LNs 5 days post challenge (**A**, **B**). These were defined as Tfh cells when being PD-1^+^ and CXCR5^+^ (**C**, **D**). Cells were also confirmed as being both ICOS^+^ and SLAM^+^ (**E**). Panels show mean value and five individual animals in a representative experiment of 3.**DOI:** [http://dx.doi.org/10.7554/eLife.06994.006](10.7554/eLife.06994.006)

Antigen size can determine duration of peptide/MHCII presentation LN APCs {#s2-3}
-------------------------------------------------------------------------

Adjuvants are thought to influence the availability of antigen in vivo and the kinetics of antigen presentation influence consequent CD4^+^ T cell proliferative, effector and memory responses ([@bib34], [@bib35]; [@bib6]). By covalently linking a traceable antigen, EαGFP ([@bib37]), to our particles we were able investigate the impact of particle size on peptide/MHCII presentation in vivo. Immunisation with 40 nm particles resulted in rapid presentation by both DCs and B cells within 6 hr of subcutaneous injection, consistent with published reports ([@bib18]; [@bib37]). Immunisation with antigen conjugated to 40 nm particles resulted in similar rapid presentation by DCs ([Figure 4A,B](#fig4){ref-type="fig"}) and B cells ([Figure 5A--C](#fig5){ref-type="fig"}) as previously observed with soluble antigen ([@bib18]; [@bib37]). An equivalent proportion of DCs also presented Eα/MHCII following immunisation with 200 nm particles. Percentages and numbers of Eα/MHCII positive DCs equivalent to soluble and 40 nm particle antigen formulations were detected at 24 and 48 hr. However, in contrast to soluble and 40 nm particle formulations, 200 nm particle challenge resulted in presentation of antigen beyond 48 hr, with 21 ± 3% of conventional DCs staining positive for Eα/MHCII at 72 hr post immunisation ([Figure 4C](#fig4){ref-type="fig"}). Presentation of antigen conjugated to 200 nm particles by the B cell compartment was slower ([Figure 5A--C](#fig5){ref-type="fig"}) but did reach levels equivalent to soluble and 40 nm particle-bound antigen. The sustained presentation observed by DCs was not evident in the B cell compartment ([Figure 5D](#fig5){ref-type="fig"}), with no significant differences in B cell presentation being detected beyond 24 hr ([Figure 5](#fig5){ref-type="fig"}). Thus, larger particles did not alter the magnitude of presentation but did prolong the duration of peptide/MHCII presentation by DCs.10.7554/eLife.06994.007Figure 4.200 nm particulate antigen challenge promotes sustained presentation of peptide/MHCII by dendritic cells (DCs).C57BL/6 mice were immunized s.c. in the footpad with 100 μg of the model antigen EαGFP alone or covalently conjugated to 40 nm or 200 nm particles. Challenge with PBS was included as a negative control. The draining popliteal LNs were harvested after 1, 6, 24, 48 and 72 hr post challenge. Flow cytometry was used to determine levels of presentation of the Eαpeptide/MHC class II complex using the monoclonal antibody YAe on CD11c^+^B220^−^ conventional DCs. The percentage and number of conventional DCs cells staining YAe^+^ is shown in (**A**) and (**B**) respectively. Representative flow cytometry plots are shown for 72 hr post challenge (**C**). Data shows the mean of three animals per time point ± standard deviation and are representative of ≥2 independent experiments. \* 40 nm vs 200 nm p = 0.012.**DOI:** [http://dx.doi.org/10.7554/eLife.06994.007](10.7554/eLife.06994.007)10.7554/eLife.06994.008Figure 5.Peptide/MHCII presentation by B cells.C57BL/6 mice were immunized s.c. in the footpad with 100 μg of the model antigen EαGFP alone or covalently conjugated to 40 nm or 200 nm particles. Challenge with PBS was included as a negative control. The draining popliteal LNs were harvested after 1, 6, 24, 48 and 72 hr post challenge. Flow cytometry was used to determine levels of presentation of the Eαpeptide/MHC class II complex using the monoclonal antibody YAe on B220^+^CD11c^−^ B cells. The percentage and number of conventional DCs cells staining YAe^+^ is shown in (**A**) and (**B**) respectively. Representative flow cytometry plots are shown for 6 and 72 hr post challenge (**C**, **D** respectively). Data shows the mean of three animals per time point ± standard deviation and are representative of ≥2 independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.06994.008](10.7554/eLife.06994.008)

Sustained peptide/MHCII presentation supports late T cell/DC interactions {#s2-4}
-------------------------------------------------------------------------

The relevance of antigen presentation at 72 hr induced by antigen conjugated to 200 nm particles was questionable given evidence from intravital imaging studies. Such studies have demonstrated that T cell priming by DCs occurs in three successive stages ([@bib40]; [@bib3]; [@bib27]; [@bib28]); stage 1 (0--8 hr) characterised by rapid T cell motility and short T/DC interactions (2--3 min); stage 2 (12--24 hr) with long-term T/DC interactions associated with the induction of priming and; stage 3 (48--72 hr) where T cells resume motility and short T/DC interactions. We therefore examined the impact of particle size on stage 3 T cell/DC interactions in vivo*.* CD11c-YFP recipients were adoptively transferred with OT-II DsRed T cells and challenged with OVA conjugated 40 nm or 200 nm particles 72 hr before lymph node imaging by MPLSM ([Video 1](#video1){ref-type="other"} and [Figure 6A](#fig6){ref-type="fig"}). Multiple short duration T cell-DC interactions (2.149 ± 0.139 min) were observed with 40 nm OVA particles ([Figure 6B](#fig6){ref-type="fig"}), comparable to that seen with naïve T cells and therefore consistent with an absence of cognate peptide/MHC and classic stage 3 motility ([@bib27]). Notably, interactions longer than 10 min were seen following 200 nm particle challenge ([Figure 6B](#fig6){ref-type="fig"}), implying that antigen driven cognate recognition was still occurring. This was further supported by the reduced T cell velocity observed in the 200 nm particle group ([Figure 6C](#fig6){ref-type="fig"}) and again in a lower T cell displacement rate ([Figure 6D](#fig6){ref-type="fig"}). T cell migratory patterns within the LNs were not significantly different between challenges as evidenced by their equivalent meandering indices ([Figure 6E](#fig6){ref-type="fig"}). Thus, the antigen presentation by DCs at 72 hr post challenge induced by antigen-conjugated 200 nm particles changed the dynamics of T cell/DC interactions, with stable, long-term interactions extending into the stage 3 time period, conventionally associated with transient interactions and rapid T cell motility ([@bib17]; [@bib27]; [@bib28]; [@bib47]).Video 1.Imaging DC and T cell behaviour after challenge with 200 nm particulate antigen.DsRed OT-II T cells were adoptively transferred into CD11cYFP recipients and footpad challenged with 100 µg of OVA conjugated to 40 nm or 200 nm particles. Popliteal LNs were imaged at 72 hr. 2 hr prior to imaging, 200 nm challenged groups were given 500 μg mIgG2a or Y3P (anti-mouse I-A). Data is representative of ≥3 individual animals and shows one of three separate areas imaged per lymph node. Scale bar represents 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.06994.009](10.7554/eLife.06994.009)10.7554/eLife.06994.00910.7554/eLife.06994.010Figure 6.DC and T cell interactions persist after challenge with 200 nm particulate antigen.DsRed OT-II T cells were adoptively transferred into CD11cYFP recipients and footpad challenged with 100 µg of OVA alone, conjugated to 40 nm or 200 nm particles. Popliteal LNs were imaged at 72 hr. Representative images following challenge (**A**) correspond with [Video 1](#video1){ref-type="other"} video file. The duration of OT-II T cell interaction with DCs was determined as intersection of DsRed and YFP signals (**B**). The velocity (**C**), displacement rate (**D**) and meandering index (**E**) for T cells were calculated. Data is representative of ≥3 individual animals and shows pooled tracks with mean values of three separate areas of a lymph node. Scale bars represent 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.06994.010](10.7554/eLife.06994.010)

Antigen size influences Tfh differentiation by sustaining peptide/MHCII presentation {#s2-5}
------------------------------------------------------------------------------------

Previous studies have demonstrated that differences in stage 2 interactions underlie the outcome of the developing immune response, with long-term (\>10 min) and short-term (\<3 min) interactions being associated with induction or priming and tolerance respectively ([@bib17]; [@bib27]; [@bib47]). Significantly, the causal link between T cell behaviour and function was subsequently revealed through disrupting TcR/pMHCII interactions with a monoclonal antibody (Y3P), which resulted in of loss long-term T/DC contacts, a return to rapid T cell motility, and a loss of T cell activation ([@bib6]). We hypothesised that the long-term T/DC interactions we observed at 72 hr post immunisation with 200 nm particles were responsible for selective Tfh differentiation. To test this hypothesis, we employed the approach described by [@bib6], using the Y3P monoclonal antibody against MHCII ([@bib6]) administered at 72 hr post challenge. Disruption of TcR/pMHCII blocked the stable interactions between T cells and DCs ([Videos 1, 2](#video1 video2){ref-type="other"}, [Figure 7A,B](#fig7){ref-type="fig"}) and increased T cell motility (data not shown). Unlike blocking stage 2 T/DC interactions ([@bib6]), robust T cell proliferative responses were observed with Y3P treatment at 72 hr ([Figure 7C](#fig7){ref-type="fig"}). However, blocking MHCII at this time point did significantly reduce the proportion of antigen specific cells co-expressing CXCR5 and PD-1 ([Figure 7D,E](#fig7){ref-type="fig"}). Therefore, we conclude that while the sustained T/DC interactions at 72 hr induced by 200 nm particles do not increase the magnitude of the resulting immune response, these interactions specifically function to alter the quality of immune response by promoting Tfh differentiation.Video 2.Disruption of DC and T cell interactions using Y3P.As for [Video 1](#video1){ref-type="other"}, DsRed OT-II T cells were adoptively transferred into CD11cYFP recipients and footpad challenged with 100 µg of OVA conjugated to 40 nm or 200 nm particles. Popliteal LNs were imaged at 72 hr. 2 hr prior to imaging, 200 nm challenged groups were given 500 µg mIgG2a or Y3P (anti-mouse I-A). Videos were acquired using a 20×/1.0 NA water-immersion objective lens and 2× zoom. Areas of interaction are shown in grey. Scale bars represent 25 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.06994.011](10.7554/eLife.06994.011)10.7554/eLife.06994.01110.7554/eLife.06994.012Figure 7.Blockade of stage 3 DC/T cell interactions following 200 nm particulate challenge prevents Tfh differentiation.Disruption of stage 3 DC/T cell interaction was demonstrated by imaging DsRed OT-II T cells adoptively transferred into CD11cYFP recipients. Mice were footpad challenged with 100 µg of OVA conjugated to 200 nm particles and popliteal LNs imaged at 72 hr. 500 µg isotype (mIgG2a) or Y3P (anti-mouse I-A) was given i.v. 2 hr prior to imaging. Representative video frames show areas of intersection in grey and highlighted by white arrows (**A**, see [Video 2](#video2){ref-type="other"} for video). Scale bars represent 25 μm. The duration of OT-II T cell interaction with DCs was determined as intersection of DsRed and YFP signals (**B**). Next, CFSE OT-II TcR Tg T cells were adoptively transferred into C57BL/6 recipients. Mice were then challenged with PBS, OVA with CFA or OVA conjugated to 200 nm particles. Mice were treated with a single dose of Y3P or isotype antibody i.v. 72 hr post challenge with particles. Draining LNs were harvested on day 5 post challenge. (**C**) Representative plots showing CFSE division of CD45.1^+^ OT-II TcR Tg T cells (gated on CD4^+^ population). Tfh cells were defined as being PD-1^+^CXCR5^+^ (**D**) and confirmed as ICOS^+^ (data not shown) for plotting Tfh proportion as a percentage of the OT-II population (**E**). Data is representative of two independent experiments with five animals per group.**DOI:** [http://dx.doi.org/10.7554/eLife.06994.012](10.7554/eLife.06994.012)

Analysis of antigen presentation kinetics following immunisation with 200 nm particles revealed that at the time of MHCII blocking (72 hr) the major population of APCs were DCs. Our multiphoton studies further confirmed that T cells were continuing to interact with DCs at this time. However, interactions with antigen presenting B cells could not be ruled out as a contributing factor, especially given their critical role in affirming and maintaining the Tfh phenotype ([@bib19]; [@bib9]; [@bib2]). To establish whether the Tfh phenotype observed following immunisation with 200 nm particles was attributable purely to DC presentation at 72 hr we assessed Tfh differentiation in the absence of cognate pMHCII B cell presentation. Immunisation of MD4 mice with 200 nm OVA particles induced equivalent proportional increases in adoptively transferred OT-II T cells as seen in C57BL/6 mice ([Figure 8A](#fig8){ref-type="fig"}). Interestingly, the Tfh phenotype induced following immunisation with 200 nm particles was not significantly altered in the absence of cognate T-B cell interactions ([Figure 8B](#fig8){ref-type="fig"}). Inclusion of pMHCII blockade at 72 hr post immunisation in MD4 mice did not influence expansion of the OT-II population ([Figure 8A](#fig8){ref-type="fig"}) but did significantly reduce the proportion of cells co-expressing CXCR5 and PD-1 ([Figure 8B](#fig8){ref-type="fig"}), reaffirming the importance of pMHCII recognition at this time. Taken together, the data implicates DCs rather than B cells as the APC population mediating this effect.10.7554/eLife.06994.013Figure 8.Cognate interactions between B and T cells are not required for early Tfh differentiation.OT-II TcR Tg T cells and were adoptively transferred into C57BL/6 or intact MD4 BcR Tg recipients. Mice were then challenged with OVA conjugated to 200 nm particles and 500 µg isotype (mIgG2a) or Y3P (anti-mouse I-A) given i.v. 72 hr later. Challenges with PBS, OVA/CFA were included as negative and positive controls. Flow cytometry was used to assess CD4^+^CD45.1^+^ OT-II cell expansion in LNs 5 days post challenge (**A**). Tfh were defined by PD-1 and CXCR5 co-expression (**B**). Panels show mean value and five individual animals, \*\*\*p \< 0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.06994.013](10.7554/eLife.06994.013)

Discussion {#s3}
==========

We have provided, in unprecedented detail, the spatiotemporal sequence of events that underlie enhanced differentiation of Tfh cells, GC response and protective Ab production by antigen formulations in vivo*.* By combining highly defined antigen delivery systems, with trackable antigen, antigen-receptor transgenics (Tgs) and state of the art imaging techniques, we revealed that antigen size impacts on the duration of peptide/MHCII presentation and the maintenance beyond 48 hr of functional DC and T cell interactions in the draining LN. The functional relevance of longer DC-T cell interactions, associated with antigen conjugated to 200 nm particles, was dissected by specifically blocking later interactions, resulting in reduced Tfh induction, while the overall magnitude of the T cell response was unaffected. Thus, the temporal characteristics of T cell stimulation can determine their functional differentiation towards a Tfh phenotype, and this can be determined by the size of the particle upon which an antigen is delivered.

Previous studies have investigated the impact of particle size on the immune response to antigen using a variety of formulations, for example lipid vesicles entrapping ([@bib4]; [@bib29]) antigens or antigens non-specifically adsorbed to the surface of inert particles ([@bib30]). The inert nature, defined size and surface functionalisation of particles employed in the present study, allowed a single variable, size, to be tested for its impact on antigen immunogenicity. Initial studies simply altering particle size revealed 200 nm particles could induce antibody production following a single immunisation. The functional importance of this observation was startlingly clear, with 200 nm particles able to impart protective anti-HA humoral immunity to influenza infection. Starting with a functional outcome relevant to vaccine design, we sought to dissect the processes by which increasing particle size impacts on the humoral response.

GC formation is central to development of high affinity antibody. GC structures support somatic hypermutation, selection of high affinity B cells and their differentiation into plasma and memory cells (for a comprehensive review see [@bib43]). Immunisation with 200 nm particles enhanced this process, explaining our initial observation of increased antibody responses. Essential in this process is the cognate interaction between Ag-specific B and T cells. The nature of this interaction has been the focus of intense research in recent years, culminating in the identification of Tfh cells and the molecules (surface and soluble) involved in their differentiation and function ([@bib24]). While both sizes of particle could equally increase antigen specific T cell responses in vivo, we found that larger particles (200 nm) induced greater Tfh differentiation than small (40 nm) particles, consistent with their role in supporting GC responses. Even though the endogenous molecular cues governing the development of Tfh cells are multifactorial ([@bib9]; [@bib24]), understanding how external stimuli can influence T cell differentiation towards this phenotype is less well understood, yet has clear implications in vaccine design. In this case we have demonstrated that simply changing the size of the Ag can clearly impact on Tfh differentiation.

A key event in the initiation of any CD4^+^ T cell response is the recognition of peptide/MHC class II complexes on DCs. The kinetics of presentation are known to influence the consequent CD4^+^ T cell proliferative, effector and memory responses induced ([@bib34], [@bib35]; [@bib6]). By covalently linking a trackable antigen to the particles we were able to map temporally in vivo peptide/MHC class II presentation and its relation to particle size. Although 200 nm particle immunisation prolonged the duration of peptide/MHC class II presentation by DCs, significantly this did not impact upon the magnitude of the T cell response compared with the smaller 40 nm particle, consistent with a previous report ([@bib13]). However, prolonged presentation was associated with the enhanced differentiation of Tfh cells. Antigen availability can dictate the magnitude of a Tfh response, with sustained presentation by B cells maintaining the Tfh phenotype ([@bib2]). Notably, immunisation with 200 nm particles resulted in sustained antigen presentation by DCs with cognate interactions with B cells being dispensable for maintenance of a Tfh phenotype. Indeed, sustained antigen presentation associated with Tfh induction has been reported in the absence of cognate interactions with B cells ([@bib11]). In the latter study, CD4^+^ T cells deficient for SAP, and therefore limited in their ability to interact with B cells, still adopted a Tfh phenotype when a second dose of soluble antigen was given 72 hr later. Presentation at this second challenge was attributed to DCs ([@bib11]), consistent with our own findings. Indeed, DCs can induce Tfh development in the absence of cognate interactions with B cells ([@bib7]) and likely represent the first step initiating Tfh differentiation ([@bib16]). Imaging draining LNs 72 hr post challenge revealed that cognate T cell/DC interactions continued at this time. Importantly the current study adds mechanistic detail to the observational data above; temporal disruption of 72 hr (stage 3) interactions, while not affecting clonal expansion, did inhibit 200 nm particle induced Tfh differentiation. Thus, increasing particle size, and sustaining presentation by DCs and their cognate interactions with T cells underpins the success of the larger particle in driving Tfh differentiation. It is unclear as to how particle size influences temporal availability of pMHCII on DCs. Particulates can impact on the mechanism of antigen uptake and therefore consequent endosomal targeting, processing and dynamics of presentation ([@bib10]; [@bib46]; [@bib15]). Thus the processing of antigen and loading of MHCII and/or its turnover at the cell surface may be contributing factors. In either case, increasing availability of TcR ligand and consequent TcR signal quantity may function in a similar way as increasing TcR dwell time in determining Tfh differentiation ([@bib42]; [@bib41]).

New delivery systems are required to generate safe and effective vaccines. This has resulted in increased focus on particle delivery systems. Our findings provide mechanistic insight as to why some formulations promote humoral immunity while others do not ([@bib30]; [@bib29]). We have linked T cell behaviour to function, demonstrating the importance of stage 3 T/DC interactions in determining the selective differentiation of T cells towards a Tfh lineage. These late stage interactions could be selectively induced using immunisation with antigen conjugated to 200 nm but not 40 nm particles, rationalising approaches to vaccine design using nanoparticles for induction of Tfh, GC formation and high affinity, class switched protective antibody. Previous studies have demonstrated that in the absence of microbial factors, parameters such as the dose and persistence of antigen can affect T cell differentiation ([@bib8]). The current data therefore explain why parameters such as the magnitude and duration of antigen presentation affect subsequent T/DC interactions and consequently determine T cell differentiation in the developing immune response.

Materials and methods {#s4}
=====================

Animals {#s4-1}
-------

hCD2-DsRed mice (gifted by D Kioussis and A Patel, National Institute for Medical Research, London) were crossed with OVA specific OT-II ([@bib1]) TCR Tg mice. MD4 BcR Tg mice ([@bib26]) on C57BL/6 backgrounds were used as a source of HEL specific B cells. 6--8 week old C57BL/6J mice were used as recipients (Harlan, Bicester, UK). CD11c-YFP mice ([@bib22]) were used a recipients in multiphoton imaging experiments. All animals were specified pathogen free and maintained under standard animal house conditions at the University of Glasgow in accordance with UK Home Office Regulations.

Antigen and bead preparations {#s4-2}
-----------------------------

The recombinant HA protein used was expressed from DNA encoding the extracellular domain of the influenza A virus subtype H1N1 (A/WSN/1933) HA (Life Technologies, Paisley, UK). OVA-HEL conjugates were prepared using gluteraldehyde to couple the chicken OVA (Worthington Biochemical, Lakewood, NJ, USA) and HEL (BBI Enzymes, Gwent, UK) as published ([@bib12]). EαGFP was produced in house as detailed previously ([@bib38]). HA, OVA, OVA-HEL or EαGFP were covalently bound to Polybead Carboxylate Microspheres (Park Scientific, Northampton, UK). Briefly, carboxylate-modified nanospheres were incubated with 2.5 mg/ml protein (EαGFP, HA, OVA or OVA-HEL) with 1 mM EDAC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide; Sigma, Dorset, UK) and 25 mM MES (2-N-morpholino ethane sulfonic acid; Sigma) overnight, in line with manufacturers instructions. Conjugation mixes were then spun in an ultracentrifuge at 4°C for 40 min. Protein concentration in the supernatant was measured to allow the amount bound to the microspheres to be calculated. Preparations were stored at 4°C and used within 3 days of preparation.

Infection with influenza virus {#s4-3}
------------------------------

Mice were immunized subcutaneously (s.c.) in the scruff. Infections with influenza virus subtype H1N1 A/WSN/1933 (WSN) were carried out in mice anesthetized with isofluorane and 20 µl of PBS containing 300 PFU of WSN virus administered intranasally (5 mice per group). This dose was used as previous experiments showed that this dose led to approximately 20% weight loss in unvaccinated animals. Viral stocks were prepared and titred in MDCK cells.

Adoptive transfer of antigen specific lymphocytes and in vivo challenge {#s4-4}
-----------------------------------------------------------------------

Adoptive transfers were performed as described previously ([@bib39]). Briefly, single cell suspensions of LNs and spleens were prepared from OT-II and MD4 mice. The proportion of Tg B and T cells was determined by flow cytometry and 2--3 × 10^6^ Tg B cells and 2--3 × 10^6^ Tg T cells adoptively transferred to age-matched C57BL/6J recipients via tail vein injection. For imaging studies, DsRed expressing CD4^+^ OT-II T cells were magnetically sorted from OT-II × hCD2-DsRed animals using mouse CD4^+^ T cell isolation kits (Miltenyi Biotec, Surrey, UK). Mice were immunized via the footpad with 130 µg of OVA-HEL conjugate alone, with CFA (Sigma, Dorset, UK), or covalently bound to carboxylate-modified microspheres. Injection with 50 μl of PBS was used as a vehicle control. Popliteal LNs were excised for ex vivo study. In MHCII blocking experiments, 500 μg Y3P (BioXcell, New Hampshire, USA) or isotype control (mouse IgG2a; BioXcell) was given via tail vein injection. In T cell/DC interaction studies, LNs were imaged 2 hr after antibody treatment.

Flow cytometry {#s4-5}
--------------

Single cell suspensions were stained using combinations of anti-CD11c-PE (N418, BD Biosciences, San Jose, CA, USA), anti-B220-PerCP (RA3-6B2, BD Biosciences), anti-I-A^b^/Ea~52-68~-biotin (YAe, eBioscience, San Diego, CA, USA), anti-CD4-eFluor450 (RM4-5, eBioscience), anti-ICOS-alexa-fluor-488 (C398.4A, BioLegend, San Diego, CA, USA), anti-PD-1-PE-Cy7 (J43, eBiosciences), anti-SLAM-APC (TC15-12F12.2, BioLegend), biotinylated anti-CXCR5 (2G8, BD Biosciences), anti-B220-eFluor450 (RA3-6B2, eBioscience), anti-GL-7-FITC (BD Biosciences), anti-FAS-PE (BD Biosciences) and biotinylated anti-IgM^a^ (DM-1, BD Biosciences). Biotinylated antibodies were detected by incubation with fluorochrome-conjugated streptavidin (BD Biosciences). Appropriate isotype controls were used throughout. Samples were acquired using a MACSQuant analyzer (Miltenyi Biotec, Surrey, UK) and analysed using FlowJo software (Tree Star Inc, Ashland, OR, USA).

Multiphoton imaging {#s4-6}
-------------------

Multiphoton imaging was carried out using a Zeiss LSM7 MP system equipped with a 20×/1.0 NA water-immersion objective lens (Zeiss UK, Cambridge, UK) and a tunable Titanium: sapphire solid-state two-photon excitation source (Chameleon Ultra II; Coherent Laser Group, Glasgow, UK) and optical parametric oscillator (OPO; Coherent Laser Group). Excised LNs were continuously bathed in warmed (37°C), oxygenated CO~2~ independent medium. A laser output of 820 nm and OPO signal at 1060 nm provided excitation of YFP CD11c^+^ and DsRed OT-II cells. Videos were acquired for 20 to 30 min with an X-Y pixel resolution of 512 × 512 in 2 μm Z increments. 3D tracking was performed using Volocity 6.1.1 (Perkin Elmer, Cambridge, UK). Values representing the mean velocity, displacement, and meandering index were calculated for each object. The intersection of DsRed and YFP objects was used to determine interaction between T cells and DCs respectively.

Statistics {#s4-7}
----------

Results are expressed as mean ± standard deviation. Gaussian distribution was confirmed by D\'Agostino & Pearson omnibus normality test prior to significance being determined by one-way ANOVA. Significance in DC-T cell interaction experiments was confirmed by Mann Whitney. Values of p \< 0.05 were regarded as significant.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

\[Editors' note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.\]

Thank you for choosing to send your work entitled "Antigen presentation kinetics control T cell/Dendritic Cell interactions and Tfh generation in vivo" for consideration at *eLife*. Your full submission has been evaluated by Tadatsugu Taniguchi (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors. Based on discussions amongst the reviewers and the individual comments below, we regret to inform you that your work will not be considered further for publication in *eLife*.

In particular, the reviewers expressed their concern that the paper is short of conceptual novelty and the role of B cells as antigen-presenting cells is not addressed.

Reviewer \#1:

T-follicular helper cells have been found to have a critical role in the formation and maintenance of germinal centers and the production of high affinity antibodies. As such, the issue of how best to induce these cells is of considerable importance to vaccine design. In this report, Benson et al. examine the use of polystyrene nanoparticle of different sizes as adjuvants. They find that larger particles lead to formation of more stable peptide MHC complexes on DCs leading to prolonged antigen presentation and longer DC/T-cell contact durations which leads to the enhanced formation of Tfh cells. Consequently antibody production, GC formation and protection from influenza virus infection are all enhanced.

1\) This is an interesting study but it almost entirely omits consideration of the critical role of B-cells as APCs in Tfh induction. Previously it has been demonstrated that Tfh form following a two-step process by which T-cells initially interact with DCs which leads to an early wave of pre-Tfh production before a second step of interaction with antigen presenting B-cells that cements the Tfh program ([@bib9]). It is surprising that the authors have only focused on the first of these two steps and not examined if there is also any effect on B-cell antigen presentation as this would widen and strengthen the article's conclusions. An effect on B-cells would not be mutually exclusive to the effects on DCs and it seems possible that both would play a role in the increased Tfh formation seen here. The authors correctly state that the Tangye group ([@bib11]) have demonstrated that it is possible to bypass the requirement for B-cells by adding more antigen and prolonging DC antigen presentation, but even here it remains controversial if DCs alone can induce PD1hi GC-Tfh and high levels of IL-21 expression ([@bib16]) and where both DCs and B-cells are present B-cells are believed to have a dominant role in Tfh formation from day 3 onwards even in the presence of large amounts of antigen (LCMV infection) ([@bib7]).

This is important as the authors make clear statements ascribing all the phenomenon to the increased antigen contact in DCs without exploring this alternative possibility. This is particularly acute in [Figure 5](#fig5){ref-type="fig"} where MHCII blocking antibodies are used to interfere with the late stage DC/T-cell contacts. At 72 hours we would also expect B-cell antigen presentation to have an important/dominant role as APCs which would also be blocked by the same antibody, currently it is not possible to say if the effects of the antibody is only by blocking DCs or both DCs and B-cells. It is also worth noting that essentially this point would be testable using the same experimental methods already used i.e. YAe antibody to see if B-cells had altered antigen presentation. Additionally some experiments using vaccination in B-cell deficient mice ideally (μMT, T-cell transfer into RAG-/- or B-cell depletion by anti-CD20) are required to make strong conclusions about the specific role of DCs in the absence of B-cells.

2\) A wider range of sizes (e.g. 40, 100, 150, 200nm) would have been useful to more precisely investigate the relationship between particulate size, DC antigen presentation and effectiveness. For example, Mottram et al. used a range of 7 bead sizes and found a bimodal distribution of effectiveness for cytokine induction suggesting that the relationship between size and efficacy may be not always be entirely linear, it would be impossible to make any similar observation in this study since only two sizes are used.

Reviewer \#2:

In this paper, Benson et al. use polystyrene nanoparticles coated with various antigens to assess the impact that size has on vaccine responses. They show that coupling the same amount of protein antigen to larger particles increases antibody production, in a similar way to using an adjuvant. This increased influenza vaccine efficacy. They demonstrate that antigen presentation By DCs is prolonged when larger particles are administered, and DCs engage T cells in longer interactions. Finally they demonstrate that blocking antigen presentation at 72hrs post immunisation decreases the proportion of Tfh cells formed. Although it is not clear how the larger particles mediate this effect. Together, this is a nice paper showing that particle size can alter vaccine efficacy, something with direct relevance to human and animal health.

There are a few issues with the manuscript in its current form that should be addressed:

1\) In 2011 in JI, Baumjohann et al. described that B cells are dispensable for initial Tfh differentiation (48hrs post vaccination) but played an important role 3.5 days after vaccination for stabilising the Tfh population. There is no discussion in this paper of whether these particles may be acting via Ag-presentation by B cells. Indeed, the evidence for changing the interaction time of T cells and DCs is clear, but the inference that the increased population of Tfh cells observed with large particles is due to these T:DC rather than T:B interactions at 72hrs post immunisation has not been demonstrated. The blocking experiments in [Figure 5](#fig5){ref-type="fig"} would disrupt all antigen presentation, not just that from DCs. A way to determine this experimentally would be to immunise B cell deficient mice (or mice whose B cells don\'t present cognate antigen) with the different sized particles and see if the expansion of the Tfh population still occurs.

2\) In [Figure 3](#fig3){ref-type="fig"} it is clear that the % of DCs presenting antigen is the same for the first 48hrs. Is the amount (or MFI) of antigen presentation similar between particle sizes, particularly at earlier time points?

Benson et al. argue that 200 nm particles prolong the duration of peptide/MHCII presentation on DCs. Does this mean that each individual MHCII molecule is maintained at the cell surface for longer? Or that larger particles deliver processed peptide at a slower rate, perhaps via an alternative route, so that MHCII can be loaded in the ER for longer? Or is it both? Do the authors know how the antigen is processed by the DC when conjugated to 40 nm or 200 nm nanoparticles? Are they processed by different compartments? The stage 3 disruption experiments in [Figure 5](#fig5){ref-type="fig"} define stage 3 simply by time after immunisation; so a slowly loaded MHCII could confound this approach. It would be worth discussing these potential confounders of the interpretation.

Reviewer \#3:

In this manuscript, the authors analyze the relative capacity of particulate antigens to optimize antibody response by inducing dendritic cell-mediated Tfh cell development. They found that:

1\) Ag conjugated 200 nm particles induced more enhanced antibody responses than 40 nm particles or soluble antigen ([Figure 1](#fig1){ref-type="fig"}). These data are redundant with previous literature showing that nanoparticles allow for the reduction of the administered antigen amount compared to immunization with soluble protein and induce strongly enhanced antibody responses (Virology Journal 2013, 10:108).

2\) Ag conjugated 200 nm particles induced prolonged presentation of antigen by dendritic cells compared with 40 nm particles or soluble antigen ([Figure 3](#fig3){ref-type="fig"}). These data are redundant with previous literature showing that particulate form of antigens are more efficiently processed and presented by different APC, including dendritic cells, macrophages and B cells, than soluble antigen (Journal of Immunology, 1996, 156:2809; Immunology and Cell Biology, 2004 82:506).

3\) Prolonged antigen presentation by dendritic cells drove Tfh cell development. These data are redundant with previous literature showing that dendritic cells support prolonged Tfh cell responses when they are forced to sustained antigen stimulation (Journal of immunology, 2011, 187:1091; Immunity, 2010, 33:241).

Although the authors provide a comprehensive examination of the in vivo T/dendritic cell interactions following in vivo administration of particulate forms of antigens, the lack of conceptual novelty tampers down the enthusiasm for this manuscript. In addition, the authors did not evaluate the contribution of antigen presentation by B cells, and this strongly compromises the conclusions of the paper.

Dendritic cell-mediated presentation launches the Tfh cell program. However, later antigen presentation by B cells is important for the maintenance of Tfh cell responses. Therefore, to demonstrate the ability of the dendritic cells to sustain Tfh cell development, the authors should perform experiments in the absence of B cells or in the absence of key cognate T-B interactions.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration. Minor issues and corrections have not been included, so there is not an accompanying Author response.\]

Thank you for choosing to send your work entitled "Antigen presentation kinetics control T cell/Dendritic Cell interactions and Tfh generation in vivo" for consideration at *eLife*. Your letter of appeal has been considered by Tadatsugu Taniguchi (Senior Editor) and a Reviewing Editor, and we are prepared to consider a revised submission.

Please perform the experiment you outline, using non-cognate B cells is a reasonable way of doing it. In addition, use a wider range of the size of nano particles, as suggested by the reviewers.

10.7554/eLife.06994.015

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

Thank you for considering our manuscript "Antigen presentation kinetics control T cell/Dendritic Cell interactions and Tfh generation in vivo". We appreciate the time and effort taken in reviewing it. Understandably, we are disappointed in the decision made by the panel, however we would welcome an opportunity to address the comments made by the referees in a revised manuscript. The two key issues raised by the referees were the lack of novelty and the role of B cell antigen presentation.

Firstly, with regard to the issue of novelty raised by Reviewer 3. While, our use of physically highly characterised particles is not novel, it is controllable, relevant to vaccination and avoids the usual empirical adjuvant approaches widely used in the literature. Our combination of manipulation of T cell/Dendritic cell interactions and the impact on resulting immune response with the analysis of this directly in vivo using real-time imaging is entirely novel. The references quoted by Reviewer 3 are purely descriptive, only demonstrating that particulate antigens are better than soluble at driving an antibody response, an approach that has been used in the vaccine field for some considerable time with no clear mechanism of action. The further work cited does not attempt to delineate the cellular mechanisms underlying how particulate antigens drive Tfh generation and hence antibody production -- the novel component of our study. Thus, our manuscript is the first causal in vivo demonstration of how T cell/dendritic cell interactions can be modulated to determine T cell phenotype in a way directly relevant to human and animal health (as stated by Reviewer 2).

With regard to the second point, we already have data requested by Reviewer 2 relating to antigen presentation by B cells. These results show no difference in presentation following immunisation with different particles, which is why we focused the current manuscript on DC. However, if you feel it would strengthen the manuscript, we could include the MD4 studies suggested by the referees, though we believe this would be negative data.

We are currently in a situation where we still lack a mechanistic basis for the function of vaccine adjuvants in vivo despite their constant use in vaccination for over 90 years. Particles form an important part of these vaccine formulations, and we believe that the current manuscript is unique in explaining their in vivo mechanism of action.

Reviewer \#1:

*1) This is an interesting study but it almost entirely omits consideration of the critical role of B-cells as APCs in Tfh induction. Previously it has been demonstrated that Tfh form following a two-step process by which T-cells initially interact with DCs which leads to an early wave of pre-Tfh production before a second step of interaction with antigen presenting B-cells that cements the Tfh program (*[@bib9]*). It is surprising that the authors have only focused on the first of these two steps and not examined if there is also any effect on B-cell antigen presentation as this would widen and strengthen the article's conclusions. An effect on B-cells would not be mutually exclusive to the effects on DCs and it seems possible that both would play a role in the increased Tfh formation seen here. The authors correctly state that the Tangye group (*[@bib11]*) have demonstrated that it is possible to bypass the requirement for B-cells by adding more antigen and prolonging DC antigen presentation, but even here it remains controversial if DCs alone can induce PD1hi GC-Tfh and high levels of IL-21 expression (*[@bib16]*) and where both DCs and B-cells are present B-cells are believed to have a dominant role in Tfh formation from day 3 onwards even in the presence of large amounts of antigen (LCMV infection) (*[@bib7]*).*

*This is important as the authors make clear statements ascribing all the phenomenon to the increased antigen contact in DCs without exploring this alternative possibility. This is particularly acute in* [*Figure 5*](#fig5){ref-type="fig"} *where MHCII blocking antibodies are used to interfere with the late stage DC/T-cell contacts. At 72 hours we would also expect B-cell antigen presentation to have an important/dominant role as APCs which would also be blocked by the same antibody, currently it is not possible to say if the effects of the antibody is only by blocking DCs or both DCs and B-cells. It is also worth noting that essentially this point would be testable using the same experimental methods already used i.e. YAe antibody to see if B-cells had altered antigen presentation. Additionally some experiments using vaccination in B-cell deficient mice ideally (μMT, T-cell transfer into RAG-/- or B-cell depletion by anti-CD20) are required to make strong conclusions about the specific role of DCs in the absence of B-cells.*

As the reviewer correctly states, antigen presentation by B cells could be examined using the methods we had employed for the DCs. We had previously generated these data but had found no significant differences in B cell antigen presentation at later times, hence we focused our interest on DCs. We have now included this pMHCII data using the YAe system tracking presentation by B cells following immunization ([Figure 5](#fig5){ref-type="fig"}). Also, as noted in the response to Reviewers 2 and 3 below, we have performed the suggested experiments in BcR Tg animals which we feel suffer less drawbacks than the B cell deficient strains suggested. These studies revealed that 200 nm particles were still able to induce a larger population of CXCR5^+^PD-1^+^ cells 5 days post immunization in the absence of cognate interactions with antigen specific B cells, consistent with our other data implicating a role for presentation by DCs.

2\) A wider range of sizes (e.g. 40, 100, 150, 200nm) would have been useful to more precisely investigate the relationship between particulate size, DC antigen presentation and effectiveness. For example Mottram et al. used a range of 7 bead sizes and found a bimodal distribution of effectiveness for cytokine induction suggesting that the relationship between size and efficacy may be not always be entirely linear, it would be impossible to make any similar observation in this study since only two sizes are used.

We now include data demonstrating the impact of wider range of particle sizes (20, 40, 100, 200 and 1000nm). Induction of antigen specific IgG2c and IgG1 are shown in [Figure 1](#fig1){ref-type="fig"}.

Reviewer \#2:

*1) In 2011 in JI Baumjohann et al. described that B cells are dispensable for initial Tfh differentiation (48hrs post vaccination) but played an important role 3.5 days after vaccination for stabilising the Tfh population. There is no discussion in this paper of whether these particles may be acting via Ag-presentation by B cells. Indeed, the evidence for changing the interaction time of T cells and DCs is clear, but the inference that the increased population of Tfh cells observed with large particles is due to these T:DC rather than T:B interactions at 72hrs post immunisation has not been demonstrated. The blocking experiments in* [*Figure 5*](#fig5){ref-type="fig"} *would disrupt all antigen presentation, not just that from DCs. A way to determine this experimentally would be to immunise B cell deficient mice (or mice whose B cells don\'t present cognate antigen) with the different sized particles and see if the expansion of the Tfh population still occurs.*

Our rationale for focusing on DCs at this time point rather than B cells had been due to pMHCII data demonstrating that not only was it prolonged in DCs but that there was no significant difference detected on B cells at this time. Unfortunately, we had not included these data in our original submission, but they are now presented in [Figure 5](#fig5){ref-type="fig"}. We agree that this alone does not directly address the contribution of cognate B cell interactions to the effect of 200 nm particles on Tfh differention. As such, we have performed the experiment suggested by the reviewer and compared 200 nm particle induction of Tfh cells in C57BL/6 and MD4 BcR transgenic mice (i.e. in the absence of cognate B cell interactions), and these studies show these cognate interactions were not required. We have now included these data along with reference to the Baumjohann et al. JI paper.

*2) In* [*Figure 3*](#fig3){ref-type="fig"} *it is clear that the % of DCs presenting antigen is the same for the first 48hrs. Is the amount (or MFI) of antigen presentation similar between particle sizes, particularly at earlier time points?*

*Benson et al. argue that 200 nm particles prolong the duration of peptide/MHCII presentation on DCs. Does this mean that each individual MHCII molecule is maintained at the cell surface for longer? Or that larger particles deliver processed peptide at a slower rate, perhaps via an alternative route, so that MHCII can be loaded in the ER for longer? Or is it both? Do the authors know how the antigen is processed by the DC when conjugated to 40 nm or 200 nm nanoparticles? Are they processed by different compartments? The stage 3 disruption experiments in* [*Figure 5*](#fig5){ref-type="fig"} *define stage 3 simply by time after immunisation; so a slowly loaded MHCII could confound this approach. It would be worth discussing these potential confounders of the interpretation.*

Similar levels of DCs pEaMHCII presentation (by MFI) are seen across the bead sizes during the first 48hrs. The levels detected are comparable with those seen on DCs in the 200 nm particle group at 72 hours ([Figure 4C](#fig4){ref-type="fig"}). A trend for lower numbers of DCs presenting pEaMHCII in the first 12 hours following immunisation with 200 nm particles was seen, however this was never statistically significant. We agree with the reviewer that the fine detail of why pMHCII is available for longer in the DC compartment is an interesting point of discussion and likely represents a combination of the processes mentioned. We have now included these points in the Discussion and referenced our recent paper investigating these issues for alum adjuvants.

Reviewer \#3:

In this manuscript, the authors analyze the relative capacity of particulate antigens to optimize antibody response by inducing dendritic cell-mediated Tfh cell development. They found that:

*1) Ag conjugated 200 nm particles induced more enhanced antibody responses than 40 nm particles or soluble antigen (*[*Figure 1*](#fig1){ref-type="fig"}*). These data are redundant with previous literature showing that nanoparticles allow for the reduction of the administered antigen amount compared to immunization with soluble protein and induce strongly enhanced antibody responses (Virology Journal 2013, 10:108).*

As the reviewer states, particulate antigens have been known to be more effective than soluble in induction of adaptive responses for decades. The data in [Figure 1](#fig1){ref-type="fig"} is included to demonstrate the phenomenon, before we moved on to address the question of why particulate antigens more effectively support an antibody response.

*2) Ag conjugated 200 nm particles induced prolonged presentation of antigen by dendritic cells compared with 40 nm particles or soluble antigen (*[*Figure 3*](#fig3){ref-type="fig"}*). These data are redundant with previous literature showing that particulate form of antigens are more efficiently processed and presented by different APC, including dendritic cells, macrophages and B cells, than soluble antigen (Journal of Immunology, 1996, 156:2809; Immunology and Cell Biology, 2004 82:506).*

While Vidard et al. (JI, 1996) extensively and elegantly demonstrated different capacities for in vitro stimulation of T cell hybridomas by B cell lines and ex-vivo bone marrow differentiated macrophages in response to particle size, the complexity of antigen presentation in vivo setting is not addressed. Thus, by directly immunizing mice with a trackable antigen, we have demonstrated when the processed antigen is presented in vivo and which physiological cell population is doing this. Hence we feel these data are not redundant but is of value to our manuscript and to the field. Additionally, the particulates used throughout our study only differ in size lacking traditional 'immunostimulatory' adjuvant properties that would confound analysis of processing, presentation and costimulation (Gamvrellis et al., Immunol Cell Biol, 2004). Thus our data allow direct comparison of in vivo availability of pMHCII in vivo when the only variable is antigen size.

3\) Prolonged antigen presentation by dendritic cells drove Tfh cell development. These data are redundant with previous literature showing that dendritic cells support prolonged Tfh cell responses when they are forced to sustained antigen stimulation (Journal of immunology, 2011, 187:1091; Immunity, 2010, 33:241).

The aim of the manuscript was not to decipher key biological events in the induction of Tfh cell differentiation. Rather the aim was to delineate the underlying process by which a single variable of an antigen delivery system (i.e. size) stimulates an adaptive immune response. Thus we believe the novelty lies in the linking of particle size to in vivo presentation kinetics/dynamics, the activation and differentiation of CD4 T cells and induction of protective antibody responses.

Although the authors provide a comprehensive examination of the in vivo T/dendritic cell interactions following in vivo administration of particulate forms of antigens, the lack of conceptual novelty tampers down the enthusiasm for this manuscript. In addition, the authors did not evaluate the contribution of antigen presentation by B cells, and this strongly compromises the conclusions of the paper.

Dendritic cell-mediated presentation launches the Tfh cell program. However, later antigen presentation by B cells is important for the maintenance of Tfh cell responses. Therefore, to demonstrate the ability of the dendritic cells to sustain Tfh cell development, the authors should perform experiments in the absence of B cells or in the absence of key cognate T-B interactions.

To address the contribution of B cells, we have included pMHCII presentation data using the YAe/EαGFP system for this population. Our rationale for focusing on DCs at this time point rather than B cells had been due to pMHCII data demonstrating that not only was it prolonged in DCs but that there was no significant difference detected on B cells at this time. Unfortunately, we had not included these data in our original submission, but they are now presented in [Figure 5](#fig5){ref-type="fig"}. However we agree that this alone does not directly address the contribution of cognate B cell interactions to the effect of 200 nm particles on Tfh differention. As such, we have performed the experiment suggested by the reviewer, and compared 200 nm particle induction of Tfh cells in C57BL/6 and MD4 BcR transgenic mice (i.e. in the absence of cognate B cell interactions -- [Figure 8](#fig8){ref-type="fig"}). Our results demonstrate that 200 nm particles were still able to induce a larger population of CXCR5^+^PD-1^+^ cells 5 days post immunization, consistent with our other data implicating a role for presentation by DCs.

[^1]: Data shows an example of a typical carbodiimide-mediated conjugation of ovalbumin to either 40 or 200 nm. Various parameters relating to a typical s.c. immunisation with 100 μg of protein are shown.
